Compounded semaglutide associated with at least 10 deaths, Novo Nordisk CEO warns

(CNN) — Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths, the chief executive of Ozempic maker Novo Nordisk warned Wednesday. “Honestly, I’m quite alarmed by what we see in the US now,” Novo Nordisk President and CEO Lars Fruergaard Jorgensen told CNN. “Patients who believe that they’re getting access to a safe product, and they believe they’re getting semaglutide .

.. I know for a fact that they are not getting semaglutide, because there’s only one semaglutide, and that’s produced by Novo Nordisk, and we don’t sell that to others.



” Javascript is required for you to be able to read premium content. Please enable it in your browser settings..